← Back to Home

AI-Designed Proteins Enter Research Services: SignalChem Licenses Light-Producing Enzyme and Binding Proteins

Monod Bio has licensed two protein technologies to SignalChem for custom research assays. The collaboration adds a route for laboratory applications of AI-designed proteins, but quantitative validation of whether this partnership can improve screening efficiency is still lacking.

By SURL BioNews

Drug discovery requires reliable measurement tools to turn hard-to-see molecular interactions into comparable signals. AI-designed proteins are gradually entering this part of the process: on August 26, 2026, Monod Bio and SignalChem Biotech announced a licensing collaboration that makes artificially designed light-producing enzymes and target-binding proteins available for use in custom research services.

According to Monod Bio’s announcement and reporting by Scientist Live, the non-exclusive license covers LuxSit luciferase and NovoBodies. SignalChem, a wholly owned subsidiary of Sino Biological, can incorporate both technologies into custom bioluminescence assay development and protein fusion services offered to third-party customers, for research use. The announcement did not disclose financial terms such as licensing fees, milestone payments, or royalties.

The two types of proteins have distinct roles. LuxSit is a luciferase designed from scratch that produces light when it reacts with a substrate and can be used to build biosensors; NovoBodies are small target-binding proteins that the company describes as highly stable. The former provides a readable signal, while the latter recognizes specific targets, providing different components for assembling assay tools around research questions.

Protein fusion services can combine different functions within a single molecular structure, potentially linking recognition with signal generation. However, how an assay is configured, which targets it is suitable for, and whether it can maintain specificity in complex samples all depend on the individual design and experimental conditions; this announcement did not list validated customer cases or assays.

The concrete step forward in this collaboration is that AI-designed proteins can reach more research customers through existing contract research services. As for the accelerated discovery benefits the company anticipates, the announcement and reporting provided no data on detection sensitivity, background signal, batch-to-batch reproducibility, or comparisons with existing methods, nor did they explain the datasets and validation processes used in the relevant AI design work. Obtaining a license alone is therefore not yet sufficient to demonstrate that these tools can shorten research and development timelines.

The uses that can currently be confirmed remain in research. Any future extension of the related assays to clinical diagnostics would require sample and performance evidence for the intended use, as well as addressing applicable regulatory requirements. For researchers, this collaboration adds another route to obtaining custom protein tools; whether those tools are suitable ultimately depends on the measured results of each assay.

References

  1. Scientist Live
  2. Monod Bio